Enclomiphene and Pitavastatin Interaction

Avoid
Mechanism-based 64% confidence

Enclomiphene and Pitavastatin have a potentially harmful interaction with 64% confidence. Both Enclomiphene and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Half-life: ~10 hours Typical dose: 12.5-25mg oral daily pct, sexual health
estrogen receptorserotonin receptor hepatotoxicpct agentteratogenic
View full profile

Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.

Half-life: ~12 hours Typical dose: 1-4 mg/day cardiovascular
aromatase aromatase inhibitorhepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
low
Pituitary
low
Heart
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Enclomiphene, Pitavastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (Enclomiphene, Pitavastatin). Monitor accordingly.

Frequently Asked Questions

Can I take Enclomiphene with Pitavastatin?

Combining Enclomiphene with Pitavastatin is not recommended. Both Enclomiphene and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and Pitavastatin safe together?

This combination carries significant risk. Both Enclomiphene and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and Pitavastatin?

Both Enclomiphene and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and Pitavastatin?

Enclomiphene has a half-life of ~10 hours and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Enclomiphene vs Pitavastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.